Diagnosis and treatment of infertility
OwnerJoanne Young Hee Kwak Kim, Alan E. Beer +1inventors
InventorsJoanne Young Hee Kwak Kim, Alan E. Beer, Alice Gilman-Sachs
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the regulation of immune responses of subjects for the diagnosis and treatment of infertility. More particularly, methods that downregulate T helper 1 (Th1) immunity or upregulate T helper 2 (Th2) immunity are used to enhance reproductive outcomes in subjects with recurrent spontaneous abortions or implantation failures by changing the balance of T helper 1 and T helper 2 immune responses. Ratios of Th1 and Th2 activities can also be used for diagnosis of infertility in these subjects.
Claims276
A method for treating infertility in a subject, the subject having a ratio of T helper 1 (Th1) immune response to T helper 2 (Th2) immune response, and the method comprises reducing the ratio of Th1 immune response to Th2 immune response in the subject to inhibit spontaneous abortion or implantation failure.
A method for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the method comprising administering a therapeutically effective dosage level of a TNF-α antagonist to the subject.
A pharmaceutical composition for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the composition comprising a TNF-α antagonist formulated in a formulation suitable for administration to the subject vaginally.
A method of enhancing the ability of a subject to carry at least one embryo to term comprising administering to the subject an effective dose of a TNF-α antagonist to inhibit TNF-A in the subject to inhibit spontaneous abortion or implantation failure.
A pharmaceutical composition for enhancing the ability of a subject to carry at least one embryo to term comprising a TNF-α antagonist to inhibit TNF-α in the subject to inhibit spontaneous abortion or implantation failure, wherein the TNF-α is formulated in formulation suitable for administration to the subject vaginally.
A method for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the method comprising administering a therapeutically effective dosage level of infliximab to the subject.
The method of 86, wherein the subject undergoes ovulation induction cycles.
A pharmaceutical composition for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the composition comprising infliximab formulated in a formulation suitable for administration to the subject vaginally.
A method for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the method comprising administering a therapeutically effective dosage level of etanercept to the subject.
A pharmaceutical composition for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the composition comprising etanercept formulated in a formulation suitable for administration to the subject vaginally.
A method for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the method comprising administering a therapeutically effective dosage level of D2E7 to the subject.
A pharmaceutical composition for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the composition comprising D2E7 formulated in al formulation suitable for administration to the subject vaginally.
A method for treating infertility in a subject to by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the method comprising administering a therapeutically effective dosage level of CDP571 to the subject.
A pharmaceutical composition for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the composition comprising CDP571 formulated in a formulation suitable for administration to the subject vaginally.
A method for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the method comprising administering a therapeutically effective dosage level of CDP870 to the subject.
A pharmaceutical composition for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the composition comprising CDP870 formulated in a formulation suitable for administration to the subject vaginally.
A method for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the method comprising administering a therapeutically effective dosage level of a thalidomide analog to the subject.
A pharmaceutical composition for treating infertility in a subject by inhibiting spontaneous abortion or implantation failures for enhancing embryo implantation, pregnancy, or birth rates, the composition comprising a thalidomide analog formulated in a formulation suitable for administration to the subject vaginally.
A method for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the method comprising administering a therapeutically effective dosage level of a phosphodiesterase type IV inhibitor to the subject.
A pharmaceutical composition for treating infertility in a subject by inhibiting spontaneous abortion or implantation failure for enhancing embryo implantation, pregnancy, or birth rates, the composition comprising a phosphodiesterase type IV inhibitor formulated in a formulation suitable for administration to the subject vaginally.
A method for diagnosing infertility in a subject with recurrent spontaneous abortions or one or more implantation failures comprising determining a ratio of Th1 and Th2 immune responses of the subject and comparing the ratio with that from subjects with normal pregnancies to determine if the subject is at risk of infertility or if the subject is suitable for treatment of the infertility by reducing ratio of Th1 to Th2 immune responses in the subject.
A diagnostic kit for diagnosing infertility with recurrent spontaneous abortions or one or more implantation failure in a subject, the kit comprising:
- (a) means for determining Th1 immune response;
- and
- (b) means for determining Th2 immune response.
A method for determining whether a treatment of infertility in a subject with recurrent spontaneous abortions or one or more implantation failures by reducing the ratio of Th1 to Th2 immune responses is having the desired effect of enhancing embryo implantation, pregnancy, or birth rates in the subject, the method comprising the steps of:
- (a) determining the ratio of the level of Th1 immune response to the level of Th2 immune response of the subject before the treatment;
- (b) determining the ratio of the level of Th1 immune response to the level of Th2 immune response of the subject after the treatment;
- (c) determining whether the ratio of Th1 to Th2 immune responses in the subject after the treatment is lower than that in the subject before the treatment to determine if the treatment has the desired effect.
A diagnostic method for determining whether a TNF-α antagonist therapy will likely enhance embryo implantation, pregnancy, or birth rates in a subject with recurrent spontaneous abortions or one or more implantation failures, the method comprising:
- (a) measuring a level of TNF-α in the subject;
- (b) determining whether the level of TNF-α in the subject is higher than that in other subjects with normal pregnancies.
A method for determining whether a TNF-α antagonist treatment of infertility in a subject with recurring spontaneous abortions or one or more implantatioin failures is having the desired effect of enhancing embryo implantation, pregnancy, or birth rates in the subject, the method comprising the steps of:
- (a) measuring the level of TNF-α in the subject before the TNF-α antagonist treatment;
- (b) measuring the level of TNF-α in the subject after the TNF-α antagonist treatment;
- (c) determining whether the level of TNF-α in the subject after the TNF-α antagonist treatment is lower than that in the subject before the treatment.
Dependencies are inferred from the claim text.